mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2022-5-71-74mrj-1349Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSВирусная микст-инфекция, осложненная острым гепатитом и токсико-аллергическим дерматитом (клинический случай)Viral mixed infection complicated by acute hepatitis and allergic toxic dermatitis (clinical case)https://orcid.org/0000-0002-1833-5357АроноваЕ. С.AronovaE. S.

Евгения Сергеевна Аронова

115522, Москва, Каширское шоссе, 34А

Evgenia S. Aronova

34A, Kashirskoe Shosse, Moscow 115522

eugpozd@mail.ruhttps://orcid.org/0000-0001-7091-2054БеловБ. С.BelovB. S.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

https://orcid.org/0000-0002-0928-3911ГридневаГ. И.GridnevaG. I.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation2022191020221657174Copyright © Аронова Е.С., Белов Б.С., Гриднева Г.И., 20222022Аронова Е.С., Белов Б.С., Гриднева Г.И.Aronova E.S., Belov B.S., Gridneva G.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1349

Вирус Эпштейна–Барр (ВЭБ) относится к семейству герпесвирусов (герпес 4-го типа) и является одним из самых распространенных и высоконтагиозных. В период пандемии новой коронавирусной болезни было обнаружено, что у пациентов, ранее инфицированных ВЭБ, COVID-19 может вызвать его реактивацию, что нередко проявляется клиникой острого гепатита. В статье представлено описание развития острого гепатита у пациента с микст-инфекцией ВЭБ и SARS-CoV-2 в сочетании с токсико-аллергической реакцией на фоне приема сульфасалазина, назначенного по поводу спондилоартрита. Особенностью данного случая являлось развитие тяжелого гепатита смешанного генеза с благоприятным исходом. Подчеркнута важность соблюдения правил лекарственного мониторинга для впервые назначаемых препаратов при COVID-19. При тяжелом течении заболевания необходимо принимать во внимание возможность микст-инфекции.

Epstein-Barr virus (EBV) belongs to the family of herpesviruses (herpes type 4) and is one of the most common and highly contagious. During the pandemic of a new coronavirus disease, it was found that in patients previously infected with EBV, COVID-19 can cause its reactivation, which is often manifested by the clinic of acute hepatitis. The article presents a clinical case of the development of acute hepatitis in a patient with mixed infection with EBV and SARS-CoV-2 in combination with allergic toxic reaction while taking sulfasalazine prescribed for spondyloarthritis. A feature of this case was the development of severe hepatitis of mixed genesis with a favorable outcome. The importance of adherence to drug monitoring rules for newly prescribed drugs for COVID-19 was emphasized. In severe cases of the disease, the possibility of mixed infection should be taken into account.

COVID-19вирус Эпштейна–Баррсиндром Стивенса–ДжонсонасульфасалазинспондилоартритгепатитSARS-CoV-2инфекционный мононуклеозCOVID-19Epstein–Barr virusStevens–Johnson syndromesulfasalazinespondyloarthritishepatitisSARS-CoV-2infectious mononucleosisReferencesNadeem A, Suresh K, Awais H, Waseem S. Epstein-Barr Virus Coinfection in COVID-19. J Investig Med High Impact Case Rep. Jan-Dec 2021;9:23247096211040626. doi: 10.1177/23247096211040626.Nadeem A, Suresh K, Awais H, Waseem S. Epstein-Barr Virus Coinfection in COVID-19. J Investig Med High Impact Case Rep. Jan-Dec 2021;9:23247096211040626. doi: 10.1177/23247096211040626.Brunet-Possenti F, Steff M, Marinho E, et al. Syndrome de Stevens-Johnson au cours d'une primo-infection par le virus d'Epstein-Barr. Ann Dermatol Venereol. 2013 Feb;140(2):112-5. doi: 10.1016/j.annder.2012.10.590. Epub 2012 Dec 10.Brunet-Possenti F, Steff M, Marinho E, et al. Syndrome de Stevens-Johnson au cours d'une primo-infection par le virus d'Epstein-Barr. Ann Dermatol Venereol. 2013 Feb;140(2):112-5. doi: 10.1016/j.annder.2012.10.590. Epub 2012 Dec 10.Федеральные клинические рекомендации по ведению больных синдромом Стивенса—Джонсона / токсическим эпидермальным некролизом. Москва: Российское общество дерматовенерологов и косметологов; 2015.Federal'nye klinicheskie rekomendatsii po vedeniyu bol'nykh sindromom Stivensa– Dzhonsona / toksicheskim epidermal'nym nekrolizom [Federal clinical guidelines for the management of patients with Stevens—Johnson syndrome / toxic epidermal necrolysis]. Moscow: Rossiiskoe obshchestvo dermatovenerologov i kosmetologov; 2015.Карташова МГ. Синдром Стивенса— Джонсона. Российский журнал кожных и венерических болезней. 2012;(6):13-7.Kartashova MG. Stephens-Johnson syndrome. Rossiiskii zhurnal kozhnykh i venericheskikh boleznei. 2012;(6):13-7. (In Russ.).Frantz R, Huang S, Are A, Motaparthi K. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management. Medicina (Kaunas). 2021 Aug 28; 57(9):895. doi: 10.3390/medicina57090895.Frantz R, Huang S, Are A, Motaparthi K. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management. Medicina (Kaunas). 2021 Aug 28; 57(9):895. doi: 10.3390/medicina57090895.Frey N, Bodmer M, Bircher A, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis in association with commonly prescribed drugs in outpatient care other than anti-epileptic drugs and antibiotics: A population-based case-control study. Drug Saf. 2019 Jan;42(1):55-66. doi: 10.1007/s40264-018-0711-x.Frey N, Bodmer M, Bircher A, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis in association with commonly prescribed drugs in outpatient care other than anti-epileptic drugs and antibiotics: A population-based case-control study. Drug Saf. 2019 Jan;42(1):55-66. doi: 10.1007/s40264-018-0711-x.Bulat V, Likic R, Pondeljak N, Azdajic MD. Pholcodine-induced Stevens–Johnson syndrome in a patient with COVID-19. Postgrad Med J. 2022 Jul;98(1161):499-500. doi: 10.1136/postgradmedj-2021-139892. Epub 2021 Apr 20.Bulat V, Likic R, Pondeljak N, Azdajic MD. Pholcodine-induced Stevens–Johnson syndrome in a patient with COVID-19. Postgrad Med J. 2022 Jul;98(1161):499-500. doi: 10.1136/postgradmedj-2021-139892. Epub 2021 Apr 20.Muhd Besari A, Lim JA, Vellaichamy PT, et al. Stevens–Johnson syndrome as a primary skin manifestation of COVID-19. Postgrad Med J. 2022 Mar;98(e2):e70. doi: 10.1136/postgradmedj-2021-140778.Muhd Besari A, Lim JA, Vellaichamy PT, et al. Stevens–Johnson syndrome as a primary skin manifestation of COVID-19. Postgrad Med J. 2022 Mar;98(e2):e70. doi: 10.1136/postgradmedj-2021-140778.Abdelgabar A, Elsayed M. Case of erythema multiforme/Stevens-Johnson syndrome: an unusual presentation of COVID-19. J R Coll Physicians Edinb. 2021 Jun;51(2):160-1. doi: 10.4997/JRCPE.2021.214.Abdelgabar A, Elsayed M. Case of erythema multiforme/Stevens-Johnson syndrome: an unusual presentation of COVID-19. J R Coll Physicians Edinb. 2021 Jun;51(2):160-1. doi: 10.4997/JRCPE.2021.214.Pagh P, Rossau AK. COVID-19 induced Stevens–Johnson syndrome. Ugeskr Laeger. 2022 Mar 7;184(10):V10210804.Pagh P, Rossau AK. COVID-19 induced Stevens–Johnson syndrome. Ugeskr Laeger. 2022 Mar 7;184(10):V10210804.Shahraki T, Hassanpour K, Arabi A, et al. Corona virus disease 2019-associated StevensJohnson syndrome: a case report. BMC Ophthalmol. 2021 Jul 12;21(1):274. doi: 10.1186/s12886-021-02033-y.Shahraki T, Hassanpour K, Arabi A, et al. Corona virus disease 2019-associated StevensJohnson syndrome: a case report. BMC Ophthalmol. 2021 Jul 12;21(1):274. doi: 10.1186/s12886-021-02033-y.Manciuc C, Lacatusu GA, Vata A, et al. Concomitance or consequence? Stevens— Johnson syndrome in COVID-19: A case report. Exp Ther Med. 2022 Apr;23(4):257. doi: 10.3892/etm.2022.11182. Epub 2022 Feb 2.Manciuc C, Lacatusu GA, Vata A, et al. Concomitance or consequence? Stevens— Johnson syndrome in COVID-19: A case report. Exp Ther Med. 2022 Apr;23(4):257. doi: 10.3892/etm.2022.11182. Epub 2022 Feb 2.Oakley AM, Krishnamurthy K. Stevens– Johnson Syndrome. https://www.ncbi.nlm.nih.gov/books/NBK459323Oakley AM, Krishnamurthy K. Stevens– Johnson Syndrome. https://www.ncbi.nlm.nih.gov/books/NBK459323Барденикова СИ, Пеньтковская ОС, Исаева ЕК. Синдром Стивенса—Джонсона — иммунная катастрофа. Русский медицинский журнал. Мать и дитя. 2019; 2(1):66–72.Bardenikova SI, Pen'tkovskaya OS, Isaeva EK. Stevens—Johnson syndrome is an immune catastrophe. Russkii meditsinskii zhurnal. Mat' i ditya. 2019;2(1):66–72. (In Russ.).Mellinger JL, Rossaro L, Naugler WE, et al. Epstein-Barr virus (EBV) related acute liver failure: a case series from the US Acute Liver Failure Study Group. Dig Dis Sci. 2014 Jul; 59(7):1630-7. doi: 10.1007/s10620-014-3029-2. Epub 2014 Jan 25.Mellinger JL, Rossaro L, Naugler WE, et al. Epstein-Barr virus (EBV) related acute liver failure: a case series from the US Acute Liver Failure Study Group. Dig Dis Sci. 2014 Jul; 59(7):1630-7. doi: 10.1007/s10620-014-3029-2. Epub 2014 Jan 25.Phipps MM, Barraza LH, LaSota ED, et al. Acute liver injury in COVID-19: prevalence and association with clinical outcomes in a large US cohort. Hepatology. 2020 Sep;72(3):807-17. doi: 10.1002/hep.31404.Phipps MM, Barraza LH, LaSota ED, et al. Acute liver injury in COVID-19: prevalence and association with clinical outcomes in a large US cohort. Hepatology. 2020 Sep;72(3):807-17. doi: 10.1002/hep.31404.Kunoutsuor SK, Laukkanen JA.Hepatic manifestations and complications of COVID-19: a systematic review and meta-analysis. J Infect. 2020 Sep;81(3):e72-e74. doi: 10.1016/j.jinf.2020.06.043. Epub 2020 Jun 21.Kunoutsuor SK, Laukkanen JA.Hepatic manifestations and complications of COVID-19: a systematic review and meta-analysis. J Infect. 2020 Sep;81(3):e72-e74. doi: 10.1016/j.jinf.2020.06.043. Epub 2020 Jun 21.Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020 May 26;323(20):2052-9. doi: 10.1001/jama.2020.6775.Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020 May 26;323(20):2052-9. doi: 10.1001/jama.2020.6775.Bongiovanni M, Zago T. Acute hepatitis caused by asymptomatic COVID-19 infection. J Infect. 2021 Jan;82(1):e25-e26. doi: 10.1016/j.jinf.2020.09.001. Epub 2020 Sep 3.Bongiovanni M, Zago T. Acute hepatitis caused by asymptomatic COVID-19 infection. J Infect. 2021 Jan;82(1):e25-e26. doi: 10.1016/j.jinf.2020.09.001. Epub 2020 Sep 3.Anirvan P, Bharali P, Gogoi M, et al. Liver injury in COVID-19: The hepatic aspect of the respiratory syndrome – what we know so far. World J Hepatol. 2020 Dec 27;12(12): 1182-97. doi: 10.4254/wjh.v12.i12.1182.Anirvan P, Bharali P, Gogoi M, et al. Liver injury in COVID-19: The hepatic aspect of the respiratory syndrome – what we know so far. World J Hepatol. 2020 Dec 27;12(12): 1182-97. doi: 10.4254/wjh.v12.i12.1182.Chen T, Song J, Liu H, et al. Positive Epstein–Barr virus detection in coronavirus disease 2019 (COVID-19) patients. Sci Rep. 2021 May 25;11(1):10902. doi: 10.1038/s41598-021-90351-y.Chen T, Song J, Liu H, et al. Positive Epstein–Barr virus detection in coronavirus disease 2019 (COVID-19) patients. Sci Rep. 2021 May 25;11(1):10902. doi: 10.1038/s41598-021-90351-y.Nadeem A, Suresh K, Awais H, Waseem S. Epstein–Barr Virus Coinfection in COVID-19. J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211040626. doi: 10.1177/23247096211040626.Nadeem A, Suresh K, Awais H, Waseem S. Epstein–Barr Virus Coinfection in COVID-19. J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211040626. doi: 10.1177/23247096211040626.Paolucci S, Cassaniti I, Novazzi F, et al; San Matteo Pavia COVID-19 Task Force. EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. Int J Infect Dis. 2021 Mar;104:315-9. doi: 10.1016/j.ijid.2020.12.051. Epub 2020 Dec 21.Paolucci S, Cassaniti I, Novazzi F, et al; San Matteo Pavia COVID-19 Task Force. EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. Int J Infect Dis. 2021 Mar;104:315-9. doi: 10.1016/j.ijid.2020.12.051. Epub 2020 Dec 21.

The authors declare that there are no conflicts of interest present.